Z
Zhejiang Hisun Sulikang Biotechnology
Specialty medical foods for digestive and metabolic disorders
About Zhejiang Hisun Sulikang Biotechnology
Zhejiang Hisun Sulikang Biotechnology Co., Ltd. is a producer of special medical and functional foods for individuals with digestive disorders, metabolic challenges, or other special disease states. The company was established in October 2015 as a wholly-owned subsidiary of the A-share listed company Zhejiang Hisun Pharmaceutical, which was founded in 1956. Hisun Sulikang was created to extend the parent company's reach into the health industry, leveraging its research and development teams and production capabilities.
The company's product line focuses on foods for special medical purposes (FSMPs), health supplements, and functional foods, available in forms like solid and liquid beverages, tablets, and freeze-dried products. One of its key achievements was the development of Yinengjia®, a protein component formula for special medical purposes, which received the first domestic registration certificate for a protein component FSMP from the State Administration for Market Regulation. The firm operates an 8,000-square-meter GMP-standardized factory with 16 production lines, including advanced automated and specialized medical food production lines.
Hisun Sulikang has secured multiple rounds of funding to support its growth. In July 2023, the company completed a financing round of over 100 million RMB from investors including Bell Capital, Yuanquan Industrial, and the team of Yang Jiyong, who serves as the company's General Manager. This was followed by another round in April 2024 for tens of millions of RMB. The company's business model is centered on the research, production, and sale of its specialized food products, serving a market that requires specially processed and formulated nutrition.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES C✓Equity / VC | Apr 2024 | $2.8M | $69M | Plank Road Capital | ↗ |
| SERIES B✓Equity / VC | Jul 2023 | $14M | $55M | Eastern Bell Capital · Source Industry | ↗ |
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Zhejiang Hisun Sulikang Biotechnology in its local ecosystem
The Zhejiang Hisun Sulikang Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Zhejiang Hisun Pharmaceutical
Eastern Bell Capital- SISource Industry
Series B and later1 investor entered at this stage
- PCPlank Road Capital
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Zhejiang Hisun Sulikang Biotechnology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Zhejiang Hisun Sulikang Biotechnology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.